Insulet Corporation (PODD) — Comparison of Productivity to Peers

Insulet Corporation's Productivity vs Peers Comparison

Table 1: Market Cap, Revenue per Employee, Income per Employee for the 12 Months period ended in Q3 2025

COMPANY NAME
TICKER
MARKET CAP
(Millions $)
REVENUE / EMPLOYEE
($) in 12 months
INCOME / EMPLOYEE
($) in 12 months
Insulet Corporation
PODD
21,521 840,633 82,067
Titan Pharmaceuticals Inc
TTNP
5 - -200,357
Embecta Corp
EMBC
688 266,947 19,357
Medtronic Plc
MDT
130,513 347,580 47,920
Dexcom Inc
DXCM
26,583 470,313 75,073
Tandem Diabetes Care Inc
TNDM
1,401 420,336 -72,590
Abbott Laboratories
ABT
218,093 384,588 122,605
Johnson and Johnson
JNJ
489,290 685,632 186,897
Nemaura Medical Inc
NMRD
0 - -343,578
Vivani Medical Inc
VANI
84 - -
Modular Medical Inc
MODD
17 - -475,350
Semler Scientific inc
SMLR
336 1,192,161 1,559,323
Myomo Inc
MYO
43 969,507 -286,191
Universal Biosensors Inc
UBI
0 60,404 -200,638
SUBTOTAL 867,053 486,540 121,948

What this table shows: Productivity metrics illustrate how effectively a company converts workforce and capital into value. Higher Revenue per Employee and Net Income per Employee generally reflect stronger operating efficiency and business scalability. First row shows Company's Productivity, followed by it's corporate peers. Click any company name in the table to view its complete financial analysis and comparison.


Insulet Corporation's Financial Strength vs Peers Comparison

Table 2: Quick Ratio, Working Capital, Debt/Equity, Asset Turnover

COMPANY NAME
TICKER
QUICK
(Ratio)
WORKING CAPITAL
(Ratio)
DEBT / EQUITY
(Ratio)
ASSET TURNOVER
(Ratio)
Insulet Corporation
PODD
- 3.09 1.02 0.77
Titan Pharmaceuticals Inc
TTNP
7.86 8.40 - -
Embecta Corp
EMBC
0.80 2.40 - 0.96
Medtronic Plc
MDT
0.72 2.03 0.58 0.38
Dexcom Inc
DXCM
0.36 1.51 1.01 0.64
Tandem Diabetes Care Inc
TNDM
1.53 2.63 1.72 1.08
Abbott Laboratories
ABT
0.65 1.70 0.45 0.60
Johnson and Johnson
JNJ
0.47 1.11 0.60 0.49
Nemaura Medical Inc
NMRD
0.13 0.38 - -
Vivani Medical Inc
VANI
1.58 1.87 - -
Modular Medical Inc
MODD
2.89 4.04 - -
Semler Scientific inc
SMLR
0.41 1.10 0.25 0.09
Myomo Inc
MYO
1.74 2.68 0.06 1.05
Universal Biosensors Inc
UBI
2.26 3.69 0.01 0.15
SUBTOTAL 0.54 1.37 0.58 0.49

What this table shows: Financial Strength ratios measure short-term liquidity (Quick Ratio, Working Capital), leverage (Debt/Equity), and operational utilization (Asset Turnover). These indicators highlight how well management allocates resources and maintains financial stability.

Insulet Corporation's Underlying Financial Totals (Revenue, Income, Employees) vs Peers Comparison

Table 3: Revenue (TTM), Net Income (TTM), Net Margin, Employees, ending Q3 2025

COMPANY NAME
TICKER
REVENUE (TTM)
Millions $
NET INCOME (TTM)
Millions $
NET MARGIN
(%)
NUMBER OF EMPLOYEES
Insulet Corporation
PODD
2,521.9 246.2 9.76% 3,000
Titan Pharmaceuticals Inc
TTNP
- -3 - 14
Embecta Corp
EMBC
1,080 78 7.25% 4,045
Medtronic Plc
MDT
34,758 4,792 13.79% 100,000
Dexcom Inc
DXCM
4,515 721 15.96% 9,600
Tandem Diabetes Care Inc
TNDM
1,009 -174 -17.27% 2,400
Abbott Laboratories
ABT
43,843 13,977 31.88% 114,000
Johnson and Johnson
JNJ
92,149 25,119 27.26% 134,400
Nemaura Medical Inc
NMRD
- -11 - 31
Vivani Medical Inc
VANI
- -26 - -
Modular Medical Inc
MODD
- -19 - 40
Semler Scientific inc
SMLR
37 48 130.8% 31
Myomo Inc
MYO
41 -12 -29.52% 42
Universal Biosensors Inc
UBI
5 -17 -332.16% 87
SUBTOTAL 177,436 44,473 25.06% 364,690

What this table shows: These totals provide the raw financial fundamentals behind the productivity, Revenue and Income per Employee ratios above. Revenue, Net Income, and Employee counts reflect the company’s scale, profitability, and workforce size. TTM refers to trailing twelve months.


Methodology & Data Source: Market Capitalization is computed from the latest available share price (delayed up to 15 minutes, depending on exchange rules) multiplied by the company’s diluted share count as reported in its filings. Revenue and Net Income figures used to calculate Revenue per Employee and Net Income per Employee are sourced directly from quarterly and annual financial statements submitted to the U.S. Securities and Exchange Commission (SEC). Employee counts are taken from the most recent Form 10-K or 10-Q disclosure and may be updated by companies in subsequent SEC submissions. All fundamentals are processed through CSIMarket.com’s XBRL normalization pipeline, which standardizes reported values across all issuers and periods.

Data lineage: SEC Filings → XBRL Extraction → CSIMarket Normalization → Productivity Metrics.

This table is one of the productivity comparisons available for Insulet Corporation. Across CSIMarket, we provide nine related comparison tables showing how Insulet Corporation performs against its Peers, including additional breakdowns visible through our main navigation bar under:
Stocks → Peers.

This page compares Insulet Corporation to its Peers based on Productivity (Market Cap, Revenue per Employee, and Net Income per Employee).

• For a deeper productivity comparison against its industry peers, visit
Insulet Corporation Productivity vs. Industry

• To review historical productivity trends for this company, including long-term changes in Revenue per Employee and Net Income per Employee, visit
Insulet Corporation Productivity History


Page last updated:

CSIMarket data powering this analysis is available across multiple delivery channels:
Data Downloads (CSV / Excel)
API & Programmatic Data Access
Enterprise Data Licensing
AI Training & Model Development License
Marketplace Distribution Options

All CSIMarket datasets are designed for analytical workflows, financial modeling, academic research, and AI/ML applications requiring normalized, reliable, and longitudinal financial time series.

To download the tables, please subscribe.